Immune checkpoint inhibitor-driven smooth muscle cell phenotypic modulation: a potential contributor to atherosclerotic risk associated with these therapies - Top-Institutions - MDSpire

Immune checkpoint inhibitor-driven smooth muscle cell phenotypic modulation: a potential contributor to atherosclerotic risk associated with these therapies

  • By

  • Abhijnan Chattopadhyay

  • Aminat O. Dosunmu

  • Darshan Reddy

  • Sree Dharma

  • Krishna Panchal

  • Callie S. Kwartler

  • Dianna M. Milewicz

  • July 13, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    University of Texas Health Science Center at Houston
    University of Texas Health Science Center at Houston

    Houston, TX

    Key Differentiators

    • Cardiology

  • #2

    Taipei Medical University Hospital
    Taipei Medical University Hospital

    Taipei, Taiwan

    Key Differentiators

    • Cardiology

  • #3

    Stephenson Cancer Center
    Stephenson Cancer Center

    Oklahoma City, OK

    Key Differentiators

    • Cardiology

  • #4

    University of Oklahoma
    University of Oklahoma

    Norman, OK

    Key Differentiators

    • Cardiology

  • #5

    National Cancer Institute
    National Cancer Institute

    Bethesda, MD

    Key Differentiators

    • Cardiology

Original Source(s)

Immune checkpoint inhibitor-driven smooth muscle cell phenotypic modulation: a potential contributor to atherosclerotic risk associated with these therapies

  • by Abhijnan Chattopadhyay, Aminat O. Dosunmu, Darshan Reddy, Sree Dharma, Krishna Panchal, Callie S. Kwartler, Dianna M. Milewicz

  • July 13, 2026

Related Content

Multimodal salvage therapy for locally advanced esophageal cancer recurrence after failed post-ESD surveillance: a case report

Subepithelial nevus and papilloma of the lacrimal caruncle: a case report and literature review

Huangjin Shuangshen decoction alleviates chronic atrophic gastritis by suppressing TNF/NF-κB signaling and promoting CFTR-associated gastric mucosal barrier repair